Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
published in: Lancet Oncology Commission
date of publication: 2012-03
language: English
main subject: chemotherapy, phase III clinical trial, multicenter clinical trial, lung cancer
Cites articles 22
- 2011-05-10
Date
Title
Article - wd:Q27851712